3 Reasons AVT is Risky and 1 Stock to Buy Instead
Over the last six months, Avnet shares have sunk to $45.83, producing a disappointing 16.4% loss - worse than the S&P 500’s 6.9% drop. This might have investors contemplating their next move.
3 Reasons to Sell SKLZ and 1 Stock to Buy Instead
What a brutal six months it’s been for Skillz. The stock has dropped 27.4% and now trades at $3.95, rattling many shareholders. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
3 Reasons to Avoid PLNT and 1 Stock to Buy Instead
While the broader market has struggled with the S&P 500 down 6.9% since October 2024, Planet Fitness has surged ahead as its stock price has climbed by 17.2% to $97.01 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.
3 Reasons QRHC is Risky and 1 Stock to Buy Instead
Quest Resource’s stock price has taken a beating over the past six months, shedding 69.2% of its value and falling to $2.48 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
3 Reasons to Sell TSN and 1 Stock to Buy Instead
Tyson Foods has been treading water for the past six months, recording a small return of 4.1% while holding steady at $62.30. However, the stock is beating the S&P 500’s 6.9% decline during that period.
Unpacking Q4 Earnings: Artivion (NYSE:AORT) In The Context Of Other Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including Artivion (NYSE:AORT) and its peers.
3 Reasons SPHR is Risky and 1 Stock to Buy Instead
Sphere Entertainment has gotten torched over the last six months - since October 2024, its stock price has dropped 44.8% to $26.99 per share. This might have investors contemplating their next move.
3 Reasons to Sell MGM and 1 Stock to Buy Instead
What a brutal six months it’s been for MGM Resorts. The stock has dropped 23.9% and now trades at $29.97, rattling many shareholders. This may have investors wondering how to approach the situation.
Spotting Winners: Teleflex (NYSE:TFX) And Surgical Equipment & Consumables - Specialty Stocks In Q4
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how surgical equipment & consumables - specialty stocks fared in Q4, starting with Teleflex (NYSE:TFX).
3 Reasons to Avoid SOUN and 1 Stock to Buy Instead
SoundHound AI has been on fire lately. In the past six months alone, the company’s stock price has rocketed 54.8%, reaching $8.22 per share. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.